Tesla CEO Elon Musk on July 2 tweeted about the company's plans to aid German drugmaker CureVac in its efforts to produce a COVID-19 vaccine.
CureVac is developing a COVID-19 vaccine that uses messenger RNA taken from the novel coronavirus to create antibodies in the bloodstream. Tesla plans to produce what Mr. Musk called "RNA microfactories" to support the project.
"In principle, I think synthetic RNA (and DNA) has amazing potential. This basically makes the solution to many diseases a software problem," Mr. Musk wrote.
Other drugmakers utilizing an RNA-centric approach to their vaccine efforts include Moderna and BioNTech.
More articles on pharmacy:
FDA releases guidance on COVID-19 vaccine approval: 4 things to know
Novartis to pay $678M to settle kickback lawsuit
Gilead's remdesivir pricing could set a disruptive industry precedent